Tumor-Associated KH-1 Antigen Production Service at CD BioGlyco

Tumor-associated KH-1 antigen is highly expressed in many tumor types and is easily recognized and attacked by immune cells on the surface of tumor cells. Therefore, the KH-1 antigen as a vaccine candidate stimulates the immune system and generates specific T-cell and B-cell immune responses, thus enhancing the ability of the human immune system to recognize and attack tumors. There have been many studies on anti-tumor vaccines based on tumor-associated KH-1 antigen, and some research progress has been achieved. In response to the growing demand for Tumor-Associated Carbohydrate Vaccine Development, CD BioGlyco has developed a versatile Glyco™ Vaccine Development Platform that enables us to offer a comprehensive Tumor-Associated Glycolipid Antigen Production Service, including our professional tumor-associated KH-1 antigen production service.

• Firstly, we synthesize the backbone part of the KH-1 antigen by chemical synthesis or enzymatic synthesis. This backbone consists of specific sugar residues, such as L-rhamnose, fucose, N-acetylglucosamine, etc.
• Subsequently, we perform glycosylation on the synthesized backbone, grafting additional sugar residues onto the backbone by synthesizing activated sugar monomers and reacting with already existing sugar chains.
• Finally, we perform appropriate protecting group removal and modification of the synthesized sugar chains. The synthesized products are purified and analyzed after obtaining the target glycan chain structure.

KH-1 antigen is an important anti-tumor vaccine candidate. The synthesized KH-1 antigen can be used for vaccine development, preparation, and clinical trials. We offer subsequent anti-tumor vaccine development services based on the produced KH-1 antigen.

Fig.1 Flowchart for the synthesis of tumor-associated KH-1 antigen. (CD BioGlyco)

Applications

• The KH-1 antigen is highly expressed in a wide range of tumor cells and can be used as a tumor-specific marker for the development and validation of tumor assays.
• The KH-1 antigen can be used to screen and evaluate the efficacy and safety of drug candidates.

Frequently Asked Question

• What is the glycan structure of the tumor-associated KH-1 antigen?

The composition of tumor-associated KH-1 antigen consists of a protein core and sugar moieties attached to it. These sugar chains are usually formed by joining monosaccharide molecules in a specific order and linkage through specific enzyme-catalyzed reactions. Common sugar molecules include glucose, galactose, mannose, and N-acetylgalactosamine.

Fig.2 Structure of the KH-1 antigen. (Li & Guo, 2017)

• How to detect synthesized KH-1 antigen?

The synthesized KH-1 antigen can be detected by a variety of methods. Immunological tests include enzyme-linked immunosorbent assay (ELISA), immunofluorescence staining, and immunohistochemistry. Mass spectrometry and nuclear magnetic resonance spectroscopy can be used to directly determine information such as molecular weight and structure of KH-1 antigen. In practical applications, a combination of methods is usually required for comprehensive detection and analysis of synthesized KH-1 antigens.

CD BioGlyco produces high-quality tumor-associated KH-1 antigens to assist you in minimizing variables in your research and obtaining more precise results. Our goal is to provide you with a reliable tool that streamlines your research process in the field of tumor-associated studies. If you would like more information about our services, please feel free to contact us.

References

1. Li, Q.; Guo, Z. Synthesis of the cancer-associated KH-1 antigen by block assembly of its backbone structure followed by one-step grafting of three fucose residues. Organic letters. 2017, 19(24): 6558-6561.
2. Li, B.H.; et al. Total synthesis of tumor-associated KH-1 antigen core nonasaccharide via photo-induced glycosylation. Organic Chemistry Frontiers. 2020, 7(10): 1255-1259.